GlassScriptPhysician profile
Tariq Gulzar
NPI 1336495662
$1,939.30
in general payments reported to CMS, 2019-2025
25 companies · $281 in 2025
The $281 reported for 2025 was more than what 83% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $182 · 2021: $331 · 2022: $205 · 2023: $220 · 2024: $376 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $877.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $316.01 | 2019-2023 | Cotempla Xr-Odt |
| Glaxosmithkline, LLC. | $252.62 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Merck Sharp & Dohme LLC | $201.62 | 2020-2025 | Gardasil 9, Vaxneuvance, Enflonsia |
| Corium, LLC | $177.35 | 2022-2025 | Azstarys |
| Verrica Pharmaceuticals INC. | $138.39 | 2023-2024 | Ycanth |
| Cranial Technologies, INC | $128.41 | 2020-2025 | Doc Band |
| Ironshore Pharmaceuticals INC. | $106.30 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $102.63 | 2023-2025 | Qelbree, Qelbree |
| Pfizer INC. | $90.58 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.85 | 2019-2021 | |
| Sanofi Pasteur INC. | $55.73 | 2021-2024 | |
| Kaleo, INC. | $42.93 | 2019-2022 | |
| Tris Pharma INC | $35.69 | 2019-2023 | Dyanavel Xr |
| Vertical Pharmaceuticals, LLC | $25.58 | 2019 | |
| Collegium Pharmaceutical, INC. | $23.15 | 2025 | Jornay Pm |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipher Pharmaceuticals US LLC | $22.18 | 2025 | Natroba, Spinosad |
| Aytu Biopharma, INC. | $21.64 | 2021 | |
| Sanofi-Aventis U.S. LLC | $21.18 | 2025 | |
| Noven Therapeutics, LLC | $17.53 | 2024 | Xelstrym |
| Hologic Sales and Service, LLC | $15.78 | 2019 | |
| Sobi, INC | $13.17 | 2019 | |
| Shire North American Group INC | $12.63 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.22 | 2019 | |
| Concordia Pharmaceuticals INC. | $11.30 | 2019 | |
| Mylan Pharmaceuticals INC. | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tariq Gulzar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.